Liggins Institute, University of Auckland, 1023 Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, 1023 Auckland, New Zealand.
Department of Pathology, Anhui Medical University, Hefei, Anhui, PR China.
Trends Endocrinol Metab. 2017 Aug;28(8):587-596. doi: 10.1016/j.tem.2017.05.003. Epub 2017 Jun 13.
The growth hormone (GH) and insulin-like growth factor-1 (IGF1) axis is the key regulator of longitudinal growth, promoting postnatal bone and muscle growth. The available data suggest that GH expression by tumour cells is associated with the aetiology and progression of various cancers such as endometrial, breast, liver, prostate, and colon cancer. Accordingly there has been increased interest in targeting GH-mediated signal transduction in a therapeutic setting. Because GH has endocrine, autocrine, and paracrine actions, therapeutic strategies will need to take into account systemic and local functions. Activation of related hormone receptors and crosstalk with other signalling pathways are also key considerations.
生长激素（GH）和胰岛素样生长因子-1（IGF1）轴是纵向生长的关键调节因子，促进出生后骨骼和肌肉的生长。现有数据表明，肿瘤细胞中 GH 的表达与多种癌症的病因和进展有关，如子宫内膜癌、乳腺癌、肝癌、前列腺癌和结肠癌。因此，人们越来越关注在治疗环境中靶向 GH 介导的信号转导。由于 GH 具有内分泌、自分泌和旁分泌作用，治疗策略需要考虑全身和局部功能。相关激素受体的激活和与其他信号通路的串扰也是关键考虑因素。
